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Abstract  
With the recent quantum leap in chemoprevention by dietary products, their use as cancer 
therapeutics is garnering worldwide attention. The concept of effortlessly fighting this deadly 
disease by gulping cups of green tea or swallowing green tea extract capsules is appreciated 
universally. Epigallocatechin-3-gallate (EGCG), a major polyphenol in green tea, has 
generated significant interest in controlling carcinogenesis due to its growth-inhibitory 
efficacy against a variety of cancers by targeting multiple signaling pathways. However, the 
success of EGCG in preclinical studies is difficult to translate into clinical trials due to issues 
of low solubility, bioavailability and an uncertain therapeutic window. The laborious and 
expensive journey of drugs from the laboratory to commercialization can be improved by 
utilizing nanoparticles as anti-cancer drug carriers. Exploitation of biopolymeric 
nanoparticles in recent years has improved EGCG’s biodistribution, stability and tumor 
selectivity, revealing its superior chemopreventive effects. This review briefly summarizes 
recent developments regarding the targets and side effects of EGCG, complications 
associated with its low bioavailability and critically analyses the application of biopolymeric 
nanoparticles encapsulating EGCG as a next generation delivery systems.  
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Introduction  
Cancer remains a major challenge owing to the diversity of affected patients, the multitude of 
sites involved, and the poor efficacy of many conventional treatments. The complexities of 
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targeting cancer at the genetic and phenotypic levels represent a challenging task [1]. Among 
the numerous treatment strategies employed, the use of nutraceuticals such as plant 
polyphenols and carotenoids holds chemopreventive potential against diverse cancer types 
[2]. Recent evidence demonstrates that polyphenols such as Curcumin, Resveratrol, 
Quercetin, etc. found in fruits, vegetables and other plant parts possess cancer-preventive 
effects and can inhibit growth of cancer cells[3-5]. Similarly, in the past few years the anti-
cancer potential of “green miraculous drink” i.e. green tea and its catechins, have been 
demonstrated in animal models involving multiple cancer types. The probable mechanisms 
identified that hamper cancer development and/or progression include inhibition of 
proliferation, initiation of apoptosis, and suppression of critical processes including invasion, 
migration and angiogenesis[6]. Therefore, there is the potential to reap the benefits of a 
pleasantly flavoured medicinal drink with multiple health benefits against a myriad of 
illnesses, including cancer[7]. 
Next to water, tea is the major consumed beverage worldwide, prepared from the dried leaves 
of camellia sinensis[8]. Alternative forms of tea can be obtained by different preparation 
techniques, including the major varieties of green, black and oolong tea. Green tea contains 
polyphenols commonly known as tea catechins, such as (-)Epigallocatechin-3-gallate 
[EGCG], (-)Epigallocatechin[EGC], (-)Epicatechin-3-gallate[ECG] and (-)Epicatechin[EC] 
which account for their major biological and pharmacological activities[9]. Catechins present 
in green tea constitute 33% of the total dry weight, which is significantly higher than red and 
oolong tea[10]. Among the catechins, EGCG is of high importance due to its abundance, 
constituting 50-80% of total catechin content in green tea, which is equivalent to 200-300 
mg/brewed cup. In addition its safety profile, easy availability and simple extraction 
procedure set it apart from other polyphenols[11]. EGCG possesses several therapeutic 
properties including anti-oxidant, anti-proliferative, anti-angiogenic and anti-carcinogenic 
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effects[12]. EGCG is an example of a class of monomeric flavan-3-ols which are 
characterized by hydroxylated aromatic rings. The presence of a pyrogallol-type structure and 
gallolyl moiety on separate rings of EGCG are strongly associated with induction of 
apoptosis, formation of reactive oxygen species and cytotoxic activities against cancer 
cells[13-15]. A plethora of epidemiological, cell-based studies, animal models and clinical 
trials have provided convincing data to support EGCG’s anti-cancer effects. EGCG 
modulates multiple cancer-related pathways, including downregulation of redox-sensitive 
transcription factors (eg NFĸB), triggering of programmed cell death through upregulation of 
Bcl-2, inhibition of angiogenic molecules inclduing VEGF, induction of cell cycle arrest at 
GO/G1 phase, and modulation of intracellular signal transduction pathways such as MAPK 
and PI3K/AKT[16]. 
Adding to the benefits of EGCG, newer data gleaned from pharmacokinetic studies suggest 
that after green tea intake a majority of the plasma population (> 75%) represents free EGCG 
rather than EGC and EC[17-19]. Interestingly no detectable amounts of EGCG or its 
metabolite 4',4'-DiMeEGCG have been detected in urine samples, despite significant plasma 
concentrations, suggesting a non-renal mediated clearance[20]. Excretion of EGCG in rats 
occurs via the hepatic route, which is the presumed route in humans as well[21]. This may 
explain the longer elimination half-life of EGCG in the body (3.4±0.3 h ) compared to other 
catechins[22]. Despite low systemic circulation, EGCG was still found in human prostate 
tissue[23] animal tissues of mice[24], foetuses, placenta[25], and the brain of rats[26] 
suggesting distribution properties that could be exploited for other medical conditions. 
Clearly EGCG possess great potential in cancer treatment and prevention but low 
bioavailability, inappropriate systemic release and bioaccessibility has limited the role EGCG 
in clinical settings. Although there are several aspects of EGCG biology, pharmacodynamics, 
and pharmacokinetics to be better understood in order to target cancer effectively (Figure 1), 
5 
 
improving the bioavailability and site specific delivery are presumed to be fundamental to 
enhancing its efficacy. 
Oral bioavailability of EGCG is less than 2% of the administered dose in rats[27] and below 
20% in mice[28]. The interpretation of EGCG bioavailability in humans is hampered by a 
lack of adequate information as most studies examined the pharmacokinetics of tea catechins. 
Oral bioavailability of EGCG is affected by several factors such as molecular weight, pH, 
biometabolic conversions, presence of metal ions, temperature and oxygen concentration[29]. 
High molecular weight catechins, a greater number of hydroxyl groups and presence of a 
gallolyl moiety in EGCG accounts for its inability to pass through the intestinal epithelium 
resulting in poor bioavailability[30]. Degradation of EGCG increases with relative humidity 
and temperature, as demonstrated using spray dried green tea extract, thus lowering its 
bioavailability[31]. EGCG is also sensitive to the pH range within the human gastrointestinal 
tract. High pH leads to oxidation of EGCG which results in the formation of the dimerized 
product the asinensins A and B, hence reducing pure EGCG’s accessibility[32-34]. 
The various processes occurring in gastrointestinal tract (GIT) including drug metabolism, 
molecular transformation, and interaction with the colonic microbiota, can impair EGCG 
absoption. Extensive modification of EGCG to its sulphated, methylated and glucuronidated 
conjugates in the small intestine, or its metabolism into phenolic acids and valerolactones by 
gut microbiota impedes EGCG entry into the blood stream[35, 36]. Samples from human 
plasma demonstrate that EGCG can be found within several hours after green tea 
consumption but is undetectable after 24h. When EGCG gets ingested with acidic food types 
such as strawberry sorbet[37] and fruit juices[38], or dietary proteins (casein, soy protein or 
skimmed milk)[39], systemic absorption and bioavailability can be impaired [40]. Apart from 
the above issues affecting bioavailability, the administration of pure EGCG through diet or 
6 
 
intraperitoneal (I.P) injection is not well tolerated due to its various side effects. These 
include hepatotoxicity and upregulation of inflammatory responses with increases in 
inflammatory markers[41]. Hence it is imperative to consider potential approaches to 
improve EGCG bioavailability, stability and therapeutic utility for future use. 
A sucessful strategy gaining momentum in pharmaceutical research is nanoencapsulation, as 
demonstrated by the exponential increase in research articles, patents, FDA approved 
products with nanoparticles, and invsestement in the nutraceuticals area. Research from 
several groups have explored the use of nanomaterials such as Gold Nanoparticles[42], 
Polymeric Nanoparticles[43], and Liposomes[44] for delivery of EGCG to facilitate drug 
entry, improve bioavailability, escape biometabolic modification and prolong circulation 
time.  
Among these nanoparticle solutions, biopolymeric nanomaterials have emerged as a spatio-
temporal therapeutic drug delivery nanocarrier which has addressed many of the above 
challenges. Polymeric nanoparticles have many advantagous properties such as enhanced 
permeation (chitosan and positively charged polymers), escape from hepatic first pass 
metabolism by delivery of therapeutics via M-cells (PLGA nanoparticles) and providing 
protection against high pH and enzymes (alginate and chitosan based polymers) in the gut. In 
addition, polymeric nanoparticles can be easily formulated and scaled up to a variety of sizes 
yielding steady drug levels compared to ceramic, gold or metal nanoparticles[45]. However, 
the major challenge for drug nanocarriers in pharmaceutical therapeutics are low drug 
encapsulation, premature release,  poor permeability across epithelial junctions, degredation 
by digestive enzymes, and instability to the varying pH found throughout the gastrointestinal 
tract[46, 47]. 
7 
 
The source of polymeric nanoparticles used for nanodelivery can be either natural (e.g. 
Chitosan, Alginate) or synthetic (e.g. polylactides, polyalkylcyanoacrylates). Naturally 
occurring polymers have advantages over synthetic polymers with respect to accessibility, 
immunogenicity, patient compliance, biodegradability and toxicity[48]. 
EGCG has been increasingly researched with each passing year for various applications as 
shown in Fig 2. Therefore the future of nanoparticle based drug deliverysystems for EGCG  
is an area of great promise.  
This review summarizes the potential benefits and drawbacks of EGCG as an anti-cancer 
nutraceutical and recent research highlighting the importance of natural polymeric 
nanocarriers in improving the effectiveness and translating EGCG research into human 
health. 
 
Biopolymer Nanoparticles: Saviour for EGCG  
Conventional methods of delivering EGCG suffer from multiple drawbacks, therefore novel 
and potent carriers are needed to tackle the intricacies of EGCG biodelivery. New evidence 
supports the notion that encapsulation of EGCG inside a matrix of polymers improves its 
pharmacokinetics and pharmacodynamics in comparison to noncapsulated EGCG. Table I 
lists the studies carried out with different polymeric nanomaterials, their synthesis 
methodologies, and the effect of EGCG loaded NPs on cancer cell lines. 
 
To deliver polyphenols such as EGCG, chitosan based nanocarriers have become the ideal 
choice owing to the availability of amino groups for further functionalisation, uncomplicated 
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drug loading methods, interaction with the gastrointestinal mucus layer and versatile routes of 
administration[49]. Several studies have investigated the bioavailability of EGCG 
encapsulated in chitosan based carriers and found them to be more proficient relative to free 
EGCG. Oral administration of chitosan tripolyphosphate nanoparticles encapsulating EGCG 
augmented intestinal absorption and elevated the jejunum and plasma exposure of EGCG by 
2.3 and 1.5 fold respectively in mice. The improved oral absorption and enhanced plasma 
exposure was believed to be due to improved drug stability within the GIT due to CS NPs 
leading to an increase in steady-state transport of EGCG across the epithilium[50]. 
Rocha et al. synthesized nanoparticles by dissolving gum arabic in water followed by 
addition of maltodextrin and EGCG. The main function of this polymeric matrix nanoparticle 
carrier system is improved drug encapsulation efficiency and improved drug stability via 
decreased oxidation. Significant degradation of EGCG has been observed within 1h at 
intestinal pH, however loading into polysaccharide nanoparticles resulted in a sigmoidal drug 
release profile with 46% of drug discharge in 10 min followed by slow release. Encapsulated 
EGCG showed significant antiproliferative activity against human prostate cancer cells 
(Du145), at very low concentrations(1-2 µM) in comparison to free EGCG [51].  
One of the methods of increasing the intestinal absorption of soluble but poorly absorbed 
nutrients is through the direct uptake of nanoparticles. Accordingly a study reported the 
synthesis of chitosan-casein-phosphopeptide nanoparticles(CPP-CSNPs) through sonication. 
During this process anionic CPP and cationic CS associate electrostatically to form 
nanostructures. Encapsulation of EGCG takes place due to hydrophobic association between 
the gallate groups of EGCG and proline groups of CPP. A key finding of this study is the use 
of a combination of polymer and peptide in order to improve EGCG’s bioavailability. 
Efficient endocytosis of chitosan nanoparticles and utilization of peptides to lessen the 
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cytotoxicity makes this nanocomposition an appropriate carrier for drug delivery. An increase 
in the cellular uptake of nanoparticles and significant increase in Papp of EGCG was observed 
in a time and dose dependent manner, most likely due to the protection of EGCG against 
intestinal enzymes afforded by the nanoparticles. Upon nanoparticle entery into lysosomes 
and exposure to acidic pH, EGCG is released after digestion of chitosan nanoparticles. 
Furthermore, reduction in transepithelial resistance in caco-2 monolayers exposed to chitosan 
nanoparticles due to compromised tight junctions is consistent with paracellular penetration 
of EGCG [52]. 
In another study carried out by the same group nanoformulation of CCP-CS NPs and the 
natural cross-linking agent from gardenia fruits, Genipin, has been used to overcome the poor 
stability and limited drug loading capacity. Crosslinking with Genipin stabilizes CPP-CS NPs 
to the harsh gastrointestinal pH range (1.2-7.4) and the presence of digestive enzymes, as 
demonstrated by the minimal changes in nanoparticle size, morphology and zeta potential 
after exposure to simulated gastric conditions. Controlled release of cargo within a preferred 
pH range was found to be dependent on the degradation of chitosan chains, which could be 
modulated by adjusting the degree of cross linkage. Cross-linked NPs released drug more 
efficiently in the intestinal environment compared to the gastric environment, which is a vital 
requirement for oral delivery. Cross-linked encapsulated CPP-CS NPs inhibited replication in 
HepG2 and BGC24 cancer cell lines to a similar degree as free EGCG, demonstrating 
retained anti-cancer properties of EGCG[53]. 
Using an alternative approach, De Pace et al. synthesized EGCG nanocarrier using 
nanoliposomes (LIPO-EGCG) made up of the cell membrane components cholesterol and 
phosphatidylcholine using a thin film hydration method. Additionally 0.2 % coating of 
chitosan over the void (CSLIPO) and drug encapsulating nanoliposomes (CSLIPO-EGCG) 
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were added to improve the stability of liposomes and EGCG. Chitosan coated nanoliposomes 
were found to be resistant to quick degradation at 4ºC in 1X PBS showing only 22% 
breakdown after 6 days. However native EGCG was completely degraded within 5 days. A 
similar delay of degradation was shown by coating nanoliposome in 10% FBS at room 
temperature for1h. Also, nanoencapsulation enabled an increase in cellular EGCG content as 
demonstrated by higher uptake in MCF-7 cells, revealing a role of chitosan as a cellular 
uptake enhancer. Sustained release of EGCG from CS-LIPO was seen at pH 5, whereas 
native EGCG showed a rapid drug dissolution rate at this pH. Coated nanoliposomes 
attenuated cell viability by 40% and induced apopotosis in up to 27% MCF-7 cells at a 
concentration of 10 µM in contrast with native EGCG[54]. 
Apart from hydrophilic polymers such as PLA and PEG, bio-nanoparticles including protein 
and polysaccharide based formulations have also been exploited to increase the 
biodistribution of EGCG. One approach utilizes the egg white protein ovalbumin and glucan 
dextran to prepare nanoparticles via the Maillard reaction. Li et al. hypothesized that 
hydrophobic protein forms a core of the nanoparticles and the shell is formed by hydrophilic 
dextran. This organization produces drug conjugated nanoparticles by self-assembly with 
EGCG. Additionally cross-linking of ovalbumin with glutaraldehyde was carried out to 
maintain NP’s structure.[55]. Crosslinking in NPs also enabled controlled drug release in 
SGF and SIF in the presence or absence of digestive enzymes when compared to conjugated 
NPs due to enhanced stability. Interstingly conjugated NPs produced similar transpeithelial 
resistivity but augmented the permeability coefficient of EGCG on Caco-2 monolayers in 
comparison to drug alone, consistent with higher cellular uptake of NPs. 
An alternative strategy utilises bovine serum albumin(BSA) to ameliorate EGCG absorption. 
BSA NPs were prepared by desolvation with loading of EGCG accomplished during 
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synthesis by simple mixing. In this method coating nanoparticles with absorption enhancers 
such as Chitosan (CBEN) and Poly-ε-lysine (PBEN) gave an added advantage of high 
cellular uptake[56]. The hydrophilicity of these polymers hinders particle aggregation at pH 
1.5-6.BSA-NPs without coating resulted in rapid release of 52.7% and 68.5% in SGF and SIF 
in one hour  respectively. In contrast, coated NPs delayed EGCG release, which was 
attributed to the enzymatic resistance created by coating them with enzyme responsive 
polymers, making them well suited for drug delivery. In addition, coating nanoparticles with 
polymers increased the storage stability of the EGCG at 60 ºC for 6 hrs when compared with 
uncoated particles. Chitosan coating resulted in marked decrease in the TEER 
(Transepithelial electric resistance) value of treated monolayers and an increase in the 
permeability coefficient of EGCG at 30 and120 minutes when compared with EGCG alone.  
In spite of the experimental benefit of using nanoparticles to deliver EGCG in-vitro 
validation of in-vivo activity is required before being able to utilize nanocarriers in clinical 
settings. To prepare chitosan nanoparticles for systemic administration, water soluble 
chitosan was allowed to first interact with EGCG and then with TPP (pentasodium 
tripolyphosphate hexahydrate) by alternative cycles of stirring and sonication. Chitosan 
facilitated the stability of NPs in an acidic environment as demonstrated by slow drug release 
in gastric juices, and enhanced drug release kinetics in simulated intestinal fluid by 5-fold 
compared to synthetic polymer encapsulation (PLA-PEG) used earlier by the same group[57]. 
In vivo prostate cancer studies were perfromed using athymic male nude mice subcutaneously 
injected with androgen positive 22Rν1 cells resulting in fast tumor growth and secretion of 
prostate cancer marker PSA in serum[58]. Nanopreparations of EGCG impeded the growth of 
tumor xenografts with 6-fold less dosage required compared to native EGCG. Furthermore, 
Chitosan nano-EGCG treatment delayed the emergence of tumor growth by approximately a 
month relative to control chitosan nanoparticles. Nanoparticle treatment was associated with 
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decreased secretion of the prostate cancer marker PSA and cleavage of DNA repair protein 
PARP. Also induction of programmed cell death in conjunction with impaired cell 
proliferation was observed after NP treatment with markedly augmented Bax levels, reduced 
Bcl-2 expression, activated caspase-3, 8 and 9, and attenuated expression of both 
proliferation markers (Ki-67 and PCNA) and angiogenesis markers (CD-31 and VEGF). The 
same group further investigated the effectiveness of nanoencapsulated EGCG against 
melanoma tumor xenografts[59]. NPs demonstrated significant inhibitory effects against 
growth of Mel 928 cells by inducing the apoptotic pathway with modulation in apoptotic 
protein levels. Treatment with NPs caused melanoma cell-cycle arrest in the G2/M phase in a 
dose dependent manner. These results were accompanied by increased expression of major 
cell cycle regulatory proteins (p21 and p27) as well as a decrease in p27 regulated cyclins 
(cyclin D1 and D3). In vivo data in a mouse model of melanoma  supported the in vitro 
findings with impairment of tumor growth and development observed and a 10-times EGCG 
dose advantage relative to the native compound.  
Building on the benefits ascribed to active targeting of cancer, Lin et al. designed NPs with 
chitosan fucose (FCS) and PEG conjugated chitosan (PCS) complexes by continous stirring 
after adding all components. PCS was prepared by dissolving depolymerised chitosan in 
DMSO and acetic acid followed by addition of methoxy PEG succinimidyl ester. In case of 
FCS, chitosan was first dissolved in 1:1 ratio of methanol and acetic acid with further 
addition of fucose. To increase the encapsulation efficiency of EGCG in chitosan conjugated 
NPs, a natural polymer gel was used. For site specific targeting fucose was preferred as its 
receptors are highly overexpressed in gastric cancer cells. These modifcations imparted 
stability to the NPs and prevented protein repulsion while increasing the interactions at 
biological interphases. Sustained drug release from conjugated nanoparticles was observed at 
pH 1.2-5.5 due to the protein stabilizing property afforded by PEG agasint proteases present 
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in gastric fluids. At higher pH (> 6.5) deprotonation of the NH2 groups in chitosan occurs, 
resulting in release of 85.5 % of EGCG within 6h. Due to the mucoadhesive properties of 
chitosan, EGCG release was more prominent around and within MKN45 cell monolayers 
resulting in signifciant reductions in cell growth. In addition EGCG-NPs exhibited 2.5 times 
higher apoptosis and decreased VEGF expression compared to EGCG alone. VEGF 
expression has been decreased to approximate 85, 71 and 53% after treatment with 
nanoparticles having EGCG concentration of 10, 20 and 40 mg/L respectively. In vivo studies 
using an orthotopic gastric tumor mouse model suggested that 40mg/kg of EGCG in 
nanoparticles was sufficient to inhibit gastric tumour growth by reducing tumor tissue spread 
and augmenting inflammatory responses, resulting in an improved survival rate[60]. 
Nanoparticle assisted combination therapies have been used in cancer treatment to capitalise 
on the synergistic effects of drugs. In one study nanocarriers were synthesized using the FDA 
approvedpolymer poly(lactic-co-glycolic acid) and milk protein casein by emulsion and 
precipitation to target breast cancer cells using intravenous drug delivery. The hydrophobic 
anti-cancer drug paclitaxel and hydrophilic EGCG were encapsulated in the PLGA core and 
casein shell of the nanocarrier respectively. Nanoparticles were also coupled with anti-EGFR 
and anti-HER2 antibodies that selectively targetted nanoparticles to cancer cells by utilising 
cell surface receptor expression. This combinatorial strategy utilising two drugs and receptor 
mediated targetting allowed sequential release of EGCG followed by paclitaxel through 
controlled means. Interestingly, in vitro results demonstrated that the encapsulation of both 
drugs together increased their cellular uptake, cytotoxic behaviour and apoptotic potential 
against paclitaxel resistant breast cancer cells (MDA-MB-231) compared to a nanocarrier 
carrying one drug only. The collective action of the drug combination amiliorated 
chemotherapy resitence exhibiting an anti-NFĸB effect resulting in reduced expression of 
NFĸB dependent genes (MMP9, VEGF1, BIRC5), and lowering efflux pump (P-gp) 
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expression. Use of these targeted combined nanocarriers circumvents paclitaxel shortcomings 
and augments its anti-cancer effect in MDA-MB-231 cells and patient-derived cancer cells. 
These studies demonstrate that combining anti-cancer drugs and polyphenols such as EGCG 
using polymeric nanocarriers is a worthwhile avenue for ongoing cancer research[61]. 
A further advance in the field of nanocarrier mediated drug delivery is the development of a 
ligand-targeted delivery system. Although laborious and costly this strategy has numerous 
advantages including increased efficacy and reduced side effects[62]. This concept was 
utilised through an insightful strategy targeting prostate cancer cells with folate 
functionalised BSA nanoparticles. Folic acid functionalisation led to a significant increase in 
EGCG-BSANP cellular uptake linked to enhanced PC-3 cell death up to 82.8% compared 
with EGCG[63].  
Taken together the promising studies cited above support the concept of anti-cancer effect of 
EGCG and empower the idea of utilizing biopolymer nanoparticles as novel and efficient 
means for protecting EGCG from the harsh gastrointestinal environment and delivering it to 
target locations. Figure 3 shows the positive effects imparted by polymeric nanomaterials 
with respect to EGCG in cancer prevention.  
Conclusion and Future Perspective 
There is increasing interest in linking lifestyle, including dietary factors, to cancer prevention 
and adjuvant treatment. Studies globally have revealed that tea flavonoids are endowed with 
multiple potential health benefits, and may represent a significant step in anti-cancer therapy. 
Despite the strong evidence of catechin anti-cancer activity in pre-clinical studies several 
issues need to be addressed when considering translating these results into human studies. To 
exploit the full potential of chemopreventive agents from tea, polymeric nanocarriers appear 
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to be an effective solution. Several nanotechnology-based formulations, some already 
approved by FDA, and others undergoing clinical trials such as Doxil, DaunoXome, 
DepoCyt, Abraxane, Genexol-PM, and BIND-014, underscorethe progress that this 
multidisciplinary field has made in developing effective anti-cancer therapies[64]. 
The concept of nanochemoprevention is a plausible approach, opening up new horizons for 
preventing carcinogensis by enhancing the stability bioavailability and targeting of anti-
cancer nurtients such as EGCG. However, filling in scientific gaps will be critical in order to 
translate their use into clinical settings, for example the super-physiologic doses used in 
various in vitro studies of EGCG leading to inconsistent results in vivo [65]. Therefore, 
administration of an appropriate concentration of drug, form of dose (capsule, brewed, tea 
extract, or accompanying a meal) and frequency of dosage need to be considered before its 
application in vivo. Low oral bioavailability of EGCG is often linked with its poor 
bioefficacy, therefore it is important to follow systematic approaches to improving 
bioavailability. Firstly, by utilizing other modes of administrationin order to escape metabolic 
conversion and conjugate formation. Secondly, by selecting and designing specific nanocargo 
to mask EGCG during its transit from the site of administration to its target tissue, without 
degradation in the harsh conditions of the GI tract[66]. 
In order to fully elucidate the role of tea catechins in vivo, various metabolites of EGCG, 
which have been documented in plasma, urine, and faeces after green tea intake, must be 
comprehensively researched to assess their chemopreventive properties, which are unknown 
at the moment. Since EGCG is versatile in nature and exerts its diverse effects by acting on 
multiple intracellular targets within cancer cells, it would be beneficial to concurrently target 
synergistic pathways through the use of combinatorial therapies. Although studies reported 
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the adjuvant effect of EGCG when used along with chemo/radio therapies,the dose of EGCG 
used in these studies limits their interpretationand hence additional efforts are needed[67].  
The currently described bipolymeric nanoparticles hold great promise, however they suffer 
from challenges including low encapsulation efficiency, instability, and limited modification 
potential. The use of inorganic nanocarriers in combination with biopolymeric materials 
could alleviate the above disadvantages. Recently, the use of FDA approved bio-protein 
based nanoparticles and nutraceutical-polymer nanocomposites have gained popularity due to 
their ability to encapsulate many hydrophobic nutraceuticals such as Curcumin, Resveratrol 
and Quercetin, however its applicability in loading and delivery of EGCG is not well-studied 
to date[68-70]. Inorganic nanocarriers like mesoporous silica nanoparticles (MSNs) have 
shown great promise in delivery of polyphenols [71-74]. We believe that MSNs also hold 
great promise in encapsulation of EGCG and can be used alone or in combination with 
biopolymers such as chitosan, alginate and lipidsto create smart nanodelivery systems for 
better pre-clinical and clinical outcome using EGCG.  
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Figure1.Major areas requiring investigation for exploiting the anti-cancer potential of EGCG 
using drug delivery. 
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Figure2. (a) Numbers of SCI-indexed publications searched on PubMed demonstrating 
increased research interest of EGCG.  (b) Graph signifies the continuous increase in 
publications referencing EGCG encapsulated nanoparticles and significant increase in 
number of publications. 
  
0
100
200
300
400
500
2005 2007 2009 2011 2013 2015
C
u
m
u
la
ti
v
e
 n
u
m
b
e
r
 o
f 
S
C
I-
in
d
e
x
e
d
 p
u
b
li
c
a
ti
o
n
s 
p
e
r
 y
e
a
r
 
Period of Publication 
0
5
10
15
20
25
30
2006 2008 2010 2012 2014
C
u
m
u
la
ti
v
e
 n
u
m
b
e
r
 o
f 
S
C
I-
in
d
e
x
e
d
 p
u
b
li
c
a
ti
o
n
s 
p
e
r
 y
e
a
r
 
Period of Publication
a) b) 
23 
 
 
Figure3. Multiple beneficial effects of biopolymeric nanomaterials encapsulating anti-cancer 
drug EGCG.EGCG: Epigallocatechin-3-gallate, SI: Small intestine.  
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Table I. Different biopolymeric nanomaterials utilized for delivery of EGCG (NPs: 
Nanoparticles 
 
Polymer 
nanomaterials 
 
 
Size 
(in nm) 
 
 
Synthesis 
method 
 
 
Loading 
Efficiency 
(%) 
 
 
Cancer 
cells/Model
s used 
 
Concentration of 
nanomaterials used in assays 
 
Ref 
 
 
Maltodextrin 
and gum arabic 
NPs 
 
 
120 ± 28 
 
 
Dissolve 
followed by 
constant 
homogenizatio
n 
 
approx 
85% 
 
 
Du145 
(Prostate) 
 
100µM:MTT assay, Caspase 
assay 
1-100 µM :Clonogenic assay 
 
 
 
51 
 
Chitosan-
caseinophosph
opeptides  
 
 
150± 4.3  
 
 
Sonication, 
Stirring 
 
24-53% 
 
Caco-2 
(Colon) 
 
 
0.002-0.5mg/mL : MTT assay 
0-500 µg/mL: Cellular uptake 
studies 
 
 
 
52 
 
Genipin-
crosslinked 
caseinophosph
opeptides-
chitosan NPs 
 
 
236± 26.3 
 
 
Sonication, 
Stirring, 
Nucleophilic 
attack 
 
 
71% 
 
 
BGC823 
(Gastric) 
HepG2 
(Liver) 
 
 
12.5-200µg/mL : Trypan blue 
assay 
 
 
 
53 
 
Chitosan-
coated 
liposomes 
 
 
 
85±6.6 
 
 
Sonication, 
Magnetic 
stirring 
 
 
90% 
 
 
MCF-7 
(Breast) 
 
0.625-10µM: MTT assay 
10µM: Apoptotic studies 
50µM, 100µM: Intracellular 
EGCG uptake 
 
 
 
54 
 
Ovalbumin-
dextran NPs 
Glutaraldehyde 
ovalbumin-
dextran 
conjugate NPs 
 
 
285  
 
339  
 
 
Maillard 
reaction, 
Stirring 
 
 
 
23.45% 
 
30% 
 
 
Caco-2 
(Colon) 
 
0.025 mg/mL: EGCG 
concentration maintained for 
TEER measurement 
 
 
 
55 
 
 
Bovine 
serum albumin 
NPs coated 
with chitosan 
 
 
300  
 
 
Desolvation 
 
32.7% 
 
 
Caco-2 
(Colon) 
 
0.023 mg/mL: EGCG 
concentration for TEER 
measurement 
 
 
 
56 
 
 
Chitosan NPs 
 
 
150-200 
 
 
Stirring , 
Sonication, 
Dialysis 
 
 
10% w/w 
 
 
22Rv1 
(Prostate 
cancer 
xenograft 
model) 
 
 
 
3mg, 6mg(Chitosan 
nanoparticle encapsulated 
EGCG)/kg body weight : Invivo 
studies 
 
 
 
58 
 
Chitosan NPs 
 
150-200 
 
Stirring , 
 
10% w/w 
 
Mel-928 
 
0-80 µM: MTT assay 
 
 
25 
 
  Sonication, 
Dialysis 
 
 (Melanoma 
cancer 
xenograft 
model 
1-4 µM: Apoptotic studies, Cell 
cycle studies 
100µg/mice: Invivo studies 
 
 
 
59 
 
Fucose-
chitosan/polyet
hylene glycol-
chitosan/gelati
n NPs 
 
 
257.5±5.1 
 
 
Gelation of 
EGCG aqueous 
solution mixed 
with 
FCS/PCS/Gel 
 
 
53.7±1.8
% 
 
 
MKN45 
(Gastric) 
 
Luc 
MKN45 
Orthotopic 
Gastric 
tumor 
model 
 
 
 
0-40mg/L: MTT assay 
10,20, 40 mg/L: Apoptotic 
studies 
40mg EGCG/kg body weight : 
Invivo studies 
 
 
 
60 
 
Poly(lactic-co-
glycolic acid) 
and Casein 
Nanocarrier 
 
190±12 
 
Emulsion and 
Precipitation 
 
76.8±9.1
% 
 
MDA-MB-
231 
MCF-7 
(Breast) 
 
40-120µM: Cytotoxic studies 
100 µM: Apoptotic studies 
 
 
61 
 
 
